These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32376370)

  • 61. Photo activation of HPPH encapsulated in "Pocket" liposomes triggers multiple drug release and tumor cell killing in mouse breast cancer xenografts.
    Sine J; Urban C; Thayer D; Charron H; Valim N; Tata DB; Schiff R; Blumenthal R; Joshi A; Puri A
    Int J Nanomedicine; 2015; 10():125-45. PubMed ID: 25565809
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Platelet-camouflaged nanococktail: Simultaneous inhibition of drug-resistant tumor growth and metastasis via a cancer cells and tumor vasculature dual-targeting strategy.
    Jing L; Qu H; Wu D; Zhu C; Yang Y; Jin X; Zheng J; Shi X; Yan X; Wang Y
    Theranostics; 2018; 8(10):2683-2695. PubMed ID: 29774068
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Glycol Chitosan-Docosahexaenoic Acid Liposomes for Drug Delivery: Synergistic Effect of Doxorubicin-Rapamycin in Drug-Resistant Breast Cancer.
    Kim MW; Niidome T; Lee R
    Mar Drugs; 2019 Oct; 17(10):. PubMed ID: 31614820
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers.
    Wang C; Sun X; Wang K; Wang Y; Yang F; Wang H
    Drug Deliv; 2016 Oct; 23(8):2697-2702. PubMed ID: 26203692
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
    Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
    Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.
    Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q
    J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
    Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
    Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Targeted multidrug delivery system to overcome chemoresistance in breast cancer.
    Tang Y; Soroush F; Tong Z; Kiani MF; Wang B
    Int J Nanomedicine; 2017; 12():671-681. PubMed ID: 28176940
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials.
    Sun B; Deng C; Meng F; Zhang J; Zhong Z
    Acta Biomater; 2016 Nov; 45():223-233. PubMed ID: 27576338
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
    Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
    Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
    [TBL] [Abstract][Full Text] [Related]  

  • 71. GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment.
    Zou Y; Xia Y; Meng F; Zhang J; Zhong Z
    Mol Pharm; 2018 Sep; 15(9):3664-3671. PubMed ID: 29570299
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Thermo-Sensitive Liposome co-Loaded of Vincristine and Doxorubicin Based on Their Similar Physicochemical Properties had Synergism on Tumor Treatment.
    Li M; Li Z; Yang Y; Wang Z; Yang Z; Li B; Xie X; Song J; Zhang H; Li Y; Gao G; Yang J; Mei X; Gong W
    Pharm Res; 2016 Aug; 33(8):1881-98. PubMed ID: 27075873
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Improved breast cancer cell-specific intracellular drug delivery and therapeutic efficacy by coupling decoration with cell penetrating peptide and SP90 peptide.
    Fan LQ; Du GX; Li PF; Li MW; Sun Y; Zhao LM
    Biomed Pharmacother; 2016 Dec; 84():1783-1791. PubMed ID: 27899251
    [TBL] [Abstract][Full Text] [Related]  

  • 74. An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance.
    Liao ZX; Chuang EY; Lin CC; Ho YC; Lin KJ; Cheng PY; Chen KJ; Wei HJ; Sung HW
    J Control Release; 2015 Jun; 208():42-51. PubMed ID: 25637705
    [TBL] [Abstract][Full Text] [Related]  

  • 75. iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability.
    Gao F; Zhang J; Fu C; Xie X; Peng F; You J; Tang H; Wang Z; Li P; Chen J
    Int J Nanomedicine; 2017; 12():4147-4162. PubMed ID: 28615942
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X; Ding L; Xu Y; Wang Y; Ping Q
    Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma.
    Yuan M; Qiu Y; Zhang L; Gao H; He Q
    Drug Deliv; 2016 May; 23(4):1171-83. PubMed ID: 26036724
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Tumor-penetrating peptide functionalization enhances the anti-glioblastoma effect of doxorubicin liposomes.
    Yang Y; Yan Z; Wei D; Zhong J; Liu L; Zhang L; Wang F; Wei X; Xie C; Lu W; He D
    Nanotechnology; 2013 Oct; 24(40):405101. PubMed ID: 24029287
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation.
    Alibolandi M; Abnous K; Sadeghi F; Hosseinkhani H; Ramezani M; Hadizadeh F
    Int J Pharm; 2016 Mar; 500(1-2):162-78. PubMed ID: 26802496
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lipid-peptide vesicle nanoscale hybrids for triggered drug release by mild hyperthermia in vitro and in vivo.
    Al-Ahmady ZS; Al-Jamal WT; Bossche JV; Bui TT; Drake AF; Mason AJ; Kostarelos K
    ACS Nano; 2012 Oct; 6(10):9335-46. PubMed ID: 22857653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.